Joseph E. Marine

Joseph E. Marine

Auto-generated profile, based on publicly available information

Joseph E. Marine

Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2009 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
USUniv.-Prof. Priv.-Doz. Dr.med.univ. Daniel Scherr
Univ.-Prof. Priv.-Doz. Dr.med.univ. Daniel Scherr
DDDarshan Dalal
Darshan Dalal
KCKaruna Chilukuri
Karuna Chilukuri
JDJun Dong
Jun Dong
DSDavid Spragg
David Spragg
JMJoseph E. Marine
Joseph E. Marine

1 November 2012 in Clinics in Geriatric Medicine
Verified
Journal Article
Closed access
GCGrant V. Chow
Grant V. Chow
JMJoseph E. Marine
Joseph E. Marine
JFJerome L. Fleg
Jerome L. Fleg

1 July 2020 in Trends in Cardiovascular Medicine
Verified
Journal Article
Open access
SSSunjeet Sidhu
Sunjeet Sidhu
JMJoseph E. Marine
Joseph E. Marine
Bradycardia is a commonly observed arrhythmia and a frequent occasion for cardiac consultation. Defined as a heart rate of less than 50-60 bpm, bradycardia can be observed as a normal phenomenon in young athletic individuals, and in patients as part of normal aging or disease (Table 1). Pathology that produces bradycardia may occur within the sinus node, atrioventricular (AV) nodal tissue, and the specialized His-Purkinje conduction system. Given the overlap of heart rate ranges with non-pathologic changes, assessment of symptoms is a critical component in the evaluation and management of bradycardia. Treatment should rarely be prescribed solely on the basis of a heart rate lower than an arbitrary cutoff or a pause above certain duration. In the 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay (referred to hereafter as the 2018 Bradycardia Guideline), there was a significant shift in emphasis from prior guidelines that emphasized device-based implantation recommendations to a focus on evaluation and management of disease states [1,2]. In this review, we will highlight the changes in the new guideline as well as describe the key elements in evaluation and management of patients presenting with bradycardia.

27 February 2023 in JACC
Verified
Journal Article
Closed access
JHJonathan C. Hsu
Jonathan C. Hsu
DDDouglas Darden
Douglas Darden
CDChengan Du
Chengan Du
JMJoseph E. Marine
Joseph E. Marine
SNSheila Nichols
Sheila Nichols
PKPeter R. Kowey
Peter R. Kowey

1 May 2019 in The American Journal of Cardiology
Verified
Journal Article
Open access
MBMoumita Bhattacharya
Moumita Bhattacharya
DLDai-Yin Lu
Dai-Yin Lu
SKShibani M. Kudchadkar
Shibani M. Kudchadkar
GGGabriela Villarreal Greenland
Gabriela Villarreal Greenland
PLPrasanth Lingamaneni
Prasanth Lingamaneni
MAM Roselle Abraham
M Roselle Abraham
Clinical risk stratification for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HC) employs rules derived from American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines or the HCM Risk-SCD model (C-index ∼0.69), which utilize a few clinical variables. We assessed whether data-driven machine learning methods that consider a wider range of variables can effectively identify HC patients with ventricular arrhythmias (VAr) that lead to SCD. We scanned the electronic health records of 711 HC patients for sustained ventricular tachycardia or ventricular fibrillation. Patients with ventricular tachycardia or ventricular fibrillation (n = 61) were tagged as VAr cases and the remaining (n = 650) as non-VAr. The 2-sample ttest and information gain criterion were used to identify the most informative clinical variables that distinguish VAr from non-VAr; patient records were reduced to include only these variables. Data imbalance stemming from low number of VAr cases was addressed by applying a combination of over- and undersampling strategies. We trained and tested multiple classifiers under this sampling approach, showing effective classification. We evaluated 93 clinical variables, of which 22 proved predictive of VAr. The ensemble of logistic regression and naïve Bayes classifiers, trained based on these 22 variables and corrected for data imbalance, was most effective in separating VAr from non-VAr cases (sensitivity = 0.73, specificity = 0.76, C-index = 0.83). Our method (HCM-VAr-Risk Model) identified 12 new predictors of VAr, in addition to 10 established SCD predictors. In conclusion, this is the first application of machine learning for identifying HC patients with VAr, using clinical attributes. Our model demonstrates good performance (C-index) compared with currently employed SCD prediction algorithms, while addressing imbalance inherent in clinical data.

22 May 2024 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
DSDanish Iltaf Satti
Danish Iltaf Satti
AKAlexander Karius
Alexander Karius
JCJeffrey Shi Kai Chan
Jeffrey Shi Kai Chan
NINino Isakadze
Nino Isakadze
RYRitu Yadav
Ritu Yadav
DSDavid Spragg
David Spragg